Loading clinical trials...
Loading clinical trials...
A Double-blind Placebo Controlled Immunogenicity Study of Vacc-4x + Lenalidomide Versus Vacc-4x With an Initial Open-label Dose Escalation Assessment of Lenalidomide in HIV-1-infected Subjects on Antiretroviral Therapy (ART).
Conditions
Interventions
Lenalidomide
Lenalidomide placebo
+2 more
Locations
4
Germany
University Medical Center Hamburg-Eppendorf
Hamburg, Hamburg, Germany
EIPMED - Gesellschaft fűr epidemiologische und klinische Forschung in der Medizin mbH Rubensstrasse 125
Berlin, State of Berlin, Germany
Charite Campus, Virchow-Klinikum Medizinische Klinik mit Schwerpunkt Infektiologie Station 59 (Suedring 11) Augustenburger Platz 1
Berlin, State of Berlin, Germany
Klinik I für Innere Medizin Klinikum Der Universität zu Köln
Cologne, Germany
Start Date
September 1, 2012
Primary Completion Date
August 1, 2014
Completion Date
August 1, 2014
Last Updated
March 8, 2017
NCT06602622
NCT06185452
NCT06902038
NCT03835546
NCT03212989
NCT04620304
Lead Sponsor
Bionor Immuno AS
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions